Cover Image

Catatonia

Show other versions (2)

Catatonia is a neuropsychiatric disorder characterized by motor, affective and cognitive-behavioural signs, which lasts from hours to days. Intensive research over the past two decades has led to catatonia being recognized as an independent diagnosis in the International Classification of Diseases,...

Full description

Saved in:
Bibliographic Details
Main Authors: Hirjak, Dusan (Author) , Rogers, Jonathan P. (Author) , Wolf, Robert Christian (Author) , Kubera, Katharina Maria (Author) , Fritze, Stefan (Author) , Wilson, Jo Ellen (Author) , Sambataro, Fabio (Author) , Fricchione, Gregory (Author) , Meyer-Lindenberg, Andreas (Author) , Ungvari, Gabor S. (Author) , Northoff, Georg (Author)
Format: Article (Journal)
Language:English
Published: 18 July 2024
In: Nature reviews. Disease Primers
Year: 2024, Volume: 10, Issue: 1, Pages: 1-18
ISSN:2056-676X
DOI:10.1038/s41572-024-00534-w
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1038/s41572-024-00534-w
Verlag, lizenzpflichtig, Volltext: https://www.nature.com/articles/s41572-024-00534-w
Get full text
Author Notes:Dusan Hirjak, Jonathan P. Rogers, Robert Christian Wolf, Katharina Maria Kubera, Stefan Fritze, Jo Ellen Wilson, Fabio Sambataro, Gregory Fricchione, Andreas Meyer-Lindenberg, Gabor S. Ungvari & Georg Northoff
Description
Summary:Catatonia is a neuropsychiatric disorder characterized by motor, affective and cognitive-behavioural signs, which lasts from hours to days. Intensive research over the past two decades has led to catatonia being recognized as an independent diagnosis in the International Classification of Diseases, 11th Revision (ICD-11) since 2022. Catatonia is found in 5-18% of inpatients on psychiatric units and 3.3% of inpatients on medical units. However, in an unknown number of patients, catatonia remains unrecognized and these patients are at risk of life-threatening complications. Hence, recognizing the symptoms of catatonia early is crucial to initiate appropriate treatment to achieve a favourable outcome. Benzodiazepines such as lorazepam and diazepam, electroconvulsive therapy, and N-methyl-d-aspartate antagonists such as amantadine and memantine, are the cornerstones of catatonia therapy. In addition, dopamine-modulating second-generation antipsychotics (for example, clozapine and aripiprazole) are effective in some patient populations. Early and appropriate treatment combined with new screening assessments has the potential to reduce the high morbidity and mortality associated with catatonia in psychiatric and non-psychiatric settings.
Item Description:Gesehen am 27.02.2025
Physical Description:Online Resource
ISSN:2056-676X
DOI:10.1038/s41572-024-00534-w

Similar Items